Cipla Ltd.

United States Food and Drug Administration (USFDA) has completed a cGMP inspection at Cipla’s Goa manufacturing facility. The inspection was conducted from September 16 to September 27, 2019. The inspection ended with 12 observations, none of which are related to data integrity.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.